MedTrace Logo

Brain Imaging and Developmental Follow up of Infants Treated With Erythropoietin

NCT01207778 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 77

Last updated 2023-08-04

Study results available
· View outcomes & findings →

Summary

Approximately 60,000 premature infants are born each year who weigh less than 1,500 grams,many of whom sustain brain damage because of their prematurity. This study is designed to evaluate the long-term developmental effects of one promising neuroprotective treatment,erythropoietin (Epo), when given in the neonatal period. Using detailed neurodevelopmental testing and state-of-the-art brain imaging, we hope to determine whether this is an effective treatment to prevent brain injury associated with prematurity, and to lay the groundwork for further studies to improve the developmental outcome of infants delivered prematurely.

Conditions

  • Prematurity

Sponsors & Collaborators

  • Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)

    collaborator NIH

  • University of New Mexico

    lead OTHER

Principal Investigators

  • Robin K Ohls, MD · University of Utah

Eligibility

Min Age
36 Months
Max Age
72 Months
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2010-03-31
Primary Completion
2016-12-31
Completion
2020-12-31

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01207778 on ClinicalTrials.gov